Pyridam Farma Tbk (PYFA) fair value: what the stock is really worth
We calculate from audited financials what Pyridam Farma Tbk is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Jul 16, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch Pyridam Farma Tbk for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
60‑month range 87.00 IDR – 1,400 IDR · fair‑value band 29.01 IDR – 58.02 IDR · the 222.00 IDR price screens above the 38.87 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 16, 2026.
Follow Pyridam Farma Tbk in your weekly email
Every Wednesday you see whether Pyridam Farma Tbk is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PT Pyridam Farma Tbk engages in the pharmaceutical business in Australia, Indonesia, Philippines, Singapore, and India. The company operates through two segments, Pharmaceutical Products, Esthetic and Toll Manufacturing Services; and Medical Equipment segments.
Show more
PT Pyridam Farma Tbk engages in the pharmaceutical business in Australia, Indonesia, Philippines, Singapore, and India. The company operates through two segments, Pharmaceutical Products, Esthetic and Toll Manufacturing Services; and Medical Equipment segments. It supplies medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR - extraction kit and extractor machine, speciment bag, sterile container, PCR machine- Gentier 48, and tube stopper. The company also provides skin care and beauty products; medical support products; and other consumer health products in the form of syrups, tablets, and capsules; sterile and injection; and sanitizers and antiseptics. In addition, it offers antiseptic solutions, betadine antiseptic skin cleansers, Betadine Vaginal Douche, Cold defense nasal and throat sprays, feminine hygiene, Guardix SG, Mouthwash and Gargle, Salep antiseptic products. PT Pyridam Farma Tbk was founded in 1976 and is headquartered in Jakarta Selatan, Indonesia. PT Pyridam Farma Tbk operates as a subsidiary of Rejuve Global Investment Pte. Ltd.
Stock analysis
Pyridam Farma Tbk (PYFA) currently trades at 222.00 IDR, while our model-based Fair Value estimate is 38.87 IDR, implying the stock looks roughly 471.1% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 90/100, which puts the evidence level at low.
Scenario range: 29.01 IDR (bear) to 58.02 IDR (bull), the price of 222.00 IDR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 15/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Pyridam Farma Tbk reported revenue of 2.8T IDR in FY2025 versus 631B IDR in FY2021, a compound +44.6%/yr. Reported net income was −380B IDR in FY2025.
Key figures
Market cap 2.5T IDR (≈ $139M) · P/S ratio 0.85 · EPS (TTM) −32.84 IDR · Net margin −13.8% · Return on equity −38.7% · Return on assets (EBIT) 5.0% · Operating margin −0.4% · Revenue (TTM) 2.8T IDR.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 66% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −82%, PYFA screens richer than that median.
Fair Value models
Bear 29.01 IDRFair Value 38.87 IDRBull 58.02 IDR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+43.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+56.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+58.3%
Start year 2020 (pandemic). Over 10 years: +28.9% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
11.6% (2020) → −5.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 630 stocks
Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score16 · Bottom 25%
Fair Value upside−83% · Bottom 25%
Profitability
Return on assets−2% · Bottom 25%
Net margin (TTM)−13% · Bottom 25%
Operating margin (TTM)0% · Bottom 25%
Growth and dividend
Revenue growth12% · Above median
Balance sheet
Debt / equity4.25× · Highest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)59· sector 20
PAST (return on equity)0· sector 27
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Pyridam Farma Tbk (PYFA) overvalued or undervalued?
As of Jul 16, 2026, our model estimates a fair value of 38.87 IDR versus a price of 222.00 IDR, about −82% upside (overvalued).
What is the fair value of PYFA?
Our model-based fair value for Pyridam Farma Tbk is 38.87 IDR (as of Jul 16, 2026), built from audited fundamentals. The current price: 222.00 IDR.
What is the quality score of PYFA?
Pyridam Farma Tbk has a Quality Score of 15/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pyridam Farma Tbk (PYFA)?
Our model-based price target is the fair value of 38.87 IDR (as of Jul 16, 2026) from 1 valuation models. Cautious scenario 29.01 IDR, optimistic scenario 58.02 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Pyridam Farma Tbk stock forecast for 2026?
Our models put fair value at 38.87 IDR, about −82% upside versus a price of 222.00 IDR (overvalued). Cautious scenario 29.01 IDR, optimistic scenario 58.02 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Pyridam Farma Tbk (PYFA)?
Pyridam Farma Tbk reported trailing-twelve-month revenue of about 2.8T IDR (latest available figure, as of Jul 16, 2026).
What is the intrinsic value of Pyridam Farma Tbk (PYFA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pyridam Farma Tbk it is 38.87 IDR per share (as of Jul 16, 2026), against a price of 222.00 IDR. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Pyridam Farma Tbk stock overvalued or undervalued in 2026?
As of Jul 16, 2026, PYFA trades above its calculated fair value: price 222.00 IDR, fair value 38.87 IDR, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PYFA?
No. The price is what the market pays today (222.00 IDR); the fair value is what the company's own numbers justify (38.87 IDR). For Pyridam Farma Tbk the two are 183.13 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Pyridam Farma Tbk worth?
The market values Pyridam Farma Tbk at about 2.5T IDR (market capitalisation, as of Jul 16, 2026). Per share that is 222.00 IDR; our models calculate a fair value of 38.87 IDR per share.
What do the bullish and bearish scenarios say about PYFA?
Our models span a range for Pyridam Farma Tbk: cautious scenario 29.01 IDR, base 38.87 IDR, optimistic 58.02 IDR per share (as of Jul 16, 2026, price 222.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pyridam Farma Tbk (PYFA)?
Balance-sheet figures for Pyridam Farma Tbk (as of Jul 16, 2026): return on equity −38.7%, debt of 4.25 per unit of equity. They feed the Quality Score of 15/100, which measures business quality independently of the share price.
How far is PYFA from its 52-week high?
Pyridam Farma Tbk trades at 222.00 IDR, about 66% below its 52-week high of 645.00 IDR and 30% above the low of 171.00 IDR (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 38.87 IDR is for.
Which stocks are comparable to Pyridam Farma Tbk?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pyridam Farma Tbk stock attractive at the current price?
The data as of Jul 16, 2026: price 222.00 IDR, calculated fair value 38.87 IDR (−82%), Quality Score 15/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PYFA calculated?
We run Pyridam Farma Tbk through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 38.87 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Pyridam Farma Tbk itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pyridam Farma Tbk (PYFA)?
The closing price on Sep 24, 2026 was 222.00 IDR. Our model-based fair value is 38.87 IDR, about −82% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pyridam Farma Tbk right now?
The price sits above even our optimistic bull case (58.02 IDR). The favourable scenario is already priced in. Weak quality (15/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (29.01 IDR to 58.02 IDR) leaves room in how you read the outcome.
Key figures of Pyridam Farma Tbk
How large is the market capitalisation of Pyridam Farma Tbk (PYFA)?
The market capitalisation of Pyridam Farma Tbk is 2.5T IDR (≈ $139M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pyridam Farma Tbk (PYFA)?
The price-to-sales ratio of Pyridam Farma Tbk is 0.85 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pyridam Farma Tbk (PYFA)?
Earnings per share at Pyridam Farma Tbk are −32.84 IDR. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Pyridam Farma Tbk (PYFA)?
The net margin of Pyridam Farma Tbk is −13.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pyridam Farma Tbk (PYFA)?
The return on equity (ROE) of Pyridam Farma Tbk is −38.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pyridam Farma Tbk (PYFA)?
On an EBIT basis the return on assets of Pyridam Farma Tbk is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pyridam Farma Tbk (PYFA)?
The operating margin of Pyridam Farma Tbk is −0.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pyridam Farma Tbk (PYFA)?
Revenue at Pyridam Farma Tbk is growing +11.8% versus a year earlier (3y avg +56.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Pyridam Farma Tbk (PYFA)?
Earnings per share at Pyridam Farma Tbk are growing +59.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Pyridam Farma Tbk (PYFA) generate?
The free cash flow of Pyridam Farma Tbk is −504B IDR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Pyridam Farma Tbk (PYFA) carry?
The net debt of Pyridam Farma Tbk is 4.7T IDR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Pyridam Farma Tbk in the live analysis
One click puts Pyridam Farma Tbk on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
